Taylor Morrison
TMHC
$60.64
+5.66%
Taylor Morrison Home Corporation is a leading American residential construction company that designs, builds, and sells single-family and multi-family homes across high-growth markets, primarily catering to entry-level, move-up, and resort lifestyle buyers. The company operates as a major national homebuilder with a distinct focus on lifestyle communities, deriving the majority of its revenue from its West segment. The current investor narrative centers on the stock's performance relative to a robust housing market, as evidenced by its recent price volatility and significant underperformance against the broader market over the past year, raising debates about its sensitivity to interest rates and execution within the cyclical residential construction sector.…
TMHC
Taylor Morrison
$60.64
Investment Opinion: Should I buy TMHC Today?
Rating & Thesis: Hold. TMHC presents a classic value trap scenario—fundamentally sound with a cheap valuation but lacking a near-term catalyst to reverse its pronounced negative momentum and severe market underperformance. The absence of a clear analyst consensus rating or price target underscores the uncertainty.
Supporting Evidence: The stock trades at a compelling trailing P/E of 7.45x and a Price/Sales of 0.72x, which appear inexpensive. The company maintains healthy profitability (12.4% ROE, 13.98% operating margin) and an exceptionally strong balance sheet (D/E of 0.37, Current Ratio of 6.24). However, these strengths are overshadowed by its -27.5% one-year relative strength versus the S&P 500 and high volatility (Beta 1.58), indicating the market is discounting these metrics due to cyclical fears.
Risks & Conditions: The two biggest risks are a housing market slowdown eroding earnings and continued sector de-rating compressing its already low multiples. This Hold rating would upgrade to a Buy if the stock demonstrates sustained technical strength by breaking above its 52-week high of $72.5, or if forward earnings estimates are revised meaningfully higher. It would downgrade to a Sell if it breaks below the $54.58 support level on deteriorating housing data. On balance, the stock appears fairly valued relative to its near-term prospects but undervalued on a long-term, through-the-cycle basis.
Sign up to view all
TMHC 12-Month Price Forecast
The outlook for TMHC is heavily contingent on the macroeconomic path for interest rates and housing. The base case of range-bound trading is most probable, given the lack of a near-term catalyst to break the stock from its downtrend, despite its cheap valuation. The strong financial foundation provides downside protection, but the high beta and cyclical nature cap upside potential in the absence of a housing recovery. The stance would upgrade to bullish on clear evidence of a housing market rebound (e.g., sustained drop in mortgage rates, rising builder confidence) and would turn bearish on a breakdown below key technical support at $54.58.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Taylor Morrison's 12-month outlook, with a consensus price target around $78.83 and implied upside of +30.0% versus the current price.
Average Target
$78.83
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$49 - $79
Analyst target range
Analyst coverage for TMHC is limited, with only 5 analysts providing estimates, which is indicative of a mid-cap stock with less institutional scrutiny that can lead to higher volatility and less efficient price discovery. The consensus focuses on financial estimates, projecting average EPS of $6.64 and revenue of $7.25 billion for the coming year, with a relatively narrow revenue range between $7.15B and $7.40B suggesting moderate uncertainty on the top line. Specific price targets, buy/hold/sell ratings, and the implied upside/downside to the current price are not available in the provided data, preventing a detailed analysis of analyst sentiment and conviction; the absence of this key data point means the market must rely more heavily on macroeconomic trends and company-specific execution updates for price direction.
Bulls vs Bears: TMHC Investment Factors
The evidence currently tilts bearish, primarily due to TMHC's severe and persistent underperformance against the broader market, which reflects deep investor concerns about the cyclical housing sector and interest rate sensitivity. The bull case rests on a fundamentally sound company with a strong balance sheet and cheap valuation, suggesting the stock may be oversold. The single most important tension in the investment debate is whether the stock's deeply discounted valuation (P/E of 7.45x) adequately compensates for the cyclical and macroeconomic risks facing the homebuilding industry, or if the market's pessimism is warranted by an impending slowdown. The resolution of this tension will depend heavily on the trajectory of interest rates and housing market data.
Bullish
- Strong Balance Sheet & Low Leverage: The company's debt-to-equity ratio of 0.37 indicates a conservative, primarily equity-financed capital structure, which provides significant financial flexibility in a cyclical industry. This is complemented by a robust current ratio of 6.24, signaling ample liquidity to navigate potential downturns.
- Attractive Absolute Valuation Multiples: TMHC trades at a trailing P/E of 7.45x and a forward P/E of 9.33x, which are generally considered value-oriented levels. The Price/Sales ratio of 0.72x and EV/EBITDA of 6.43x further reinforce an inexpensive valuation profile on absolute measures.
- Healthy Profitability Margins: The company demonstrates solid operational efficiency with a net margin of 9.63% and an operating margin of 13.98%. A return on equity of 12.4% confirms satisfactory profitability generation from its capital base.
- Recent Technical Rebound Attempt: The stock's 5.66% single-day jump from $57.39 to $60.64, contributing to a 4.3% gain over the past month, suggests a potential reversal from recent lows. This move, while still lagging the market, indicates some buying interest at depressed levels.
Bearish
- Severe Relative Underperformance: TMHC has dramatically underperformed the S&P 500, with a -27.46% relative strength over the past year and -8.77% over the past six months. This persistent weakness signals deep-seated investor skepticism about the sector or company-specific prospects.
- High Volatility & Cyclical Risk: A beta of 1.581 confirms the stock is 58% more volatile than the market, making it a higher-risk proposition. The 22.2% maximum drawdown highlights the substantial downside moves inherent in its trading pattern, typical of a cyclical homebuilder.
- Stagnant Growth Expectations: Analyst revenue estimates for the coming year cluster in a narrow range around $7.25B, implying expectations for stable, low-single-digit growth at best. The absence of a strong growth narrative limits potential for multiple expansion.
- Limited Analyst Coverage & Sentiment: With only 5 analysts providing estimates, TMHC suffers from less institutional scrutiny, which can lead to higher volatility and less efficient price discovery. The lack of published price targets and consensus ratings further obscures professional sentiment.
TMHC Technical Analysis
The stock is in a pronounced downtrend and consolidation phase, having declined 1.88% over the past six months and underperforming the S&P 500 by 8.77% during that period. Currently trading at $60.64, it sits approximately 16% below its 52-week high of $72.5 and about 11% above its 52-week low of $54.58, positioning it in the lower-middle of its annual range which suggests it is neither deeply oversold nor exhibiting strong momentum. Recent momentum shows conflicting signals, with a 4.3% gain over the past month contrasting sharply with a 4.16% loss over the past three months; this one-month rally, occurring alongside a significant 5.66% single-day jump from $57.39, may indicate a potential rebound attempt but remains weak relative to the S&P 500's 7.36% monthly gain, as reflected in the negative 3.06 relative strength. Key technical levels are clearly defined with major resistance at the $72.5 high and support near the $54.58 low; a sustained breakout above $72.5 would signal a reversal of the longer-term downtrend, while a breakdown below $54.58 could precipitate a new leg lower. The stock's high beta of 1.581 confirms its status as 58% more volatile than the market, which is critical for risk assessment, and its 22.2% maximum drawdown highlights the substantial downside moves inherent in its trading pattern.
Beta
1.58
1.58x market volatility
Max Drawdown
-22.2%
Largest decline past year
52-Week Range
$55-$73
Price range past year
Annual Return
+7.4%
Cumulative gain past year
| Period | TMHC Return | S&P 500 |
|---|---|---|
| 1m | +4.3% | +9.5% |
| 3m | -4.2% | +2.7% |
| 6m | -1.9% | +5.8% |
| 1y | +7.4% | +34.9% |
| ytd | +3.1% | +4.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TMHC Fundamental Analysis
Revenue and growth trajectory analysis is constrained as specific quarterly revenue and YoY growth figures are not available in the provided dataset; however, analyst estimates point to expected full-year revenue of approximately $7.25 billion, with a tight range between $7.15B and $7.40B, suggesting expectations for stable, low-single-digit growth. The company is profitable with a trailing net margin of 9.63% and a gross margin of 23.03%, while its operating margin stands at 13.98%, indicating healthy conversion of revenue to operating income; the forward P/E of 9.33, being higher than the trailing P/E of 7.45, implies analysts anticipate earnings growth in the coming year. Balance sheet health appears strong with a robust current ratio of 6.24, signaling ample short-term liquidity, and a conservative debt-to-equity ratio of 0.37, which points to a primarily equity-financed structure and low financial risk; the return on equity of 12.4% and return on assets of 7.6% demonstrate satisfactory efficiency in generating profits from its capital base.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TMHC Overvalued?
Given the company's positive net margin, the primary valuation metric selected is the Price-to-Earnings (P/E) ratio. The stock trades at a trailing P/E of 7.45x and a forward P/E of 9.33x; the higher forward multiple suggests the market is pricing in expected earnings growth, as corroborated by the analyst EPS estimate of $6.64 for the forward period. Compared to typical sector averages, which are not provided in the dataset, a P/E below 10x generally suggests a value-oriented multiple; the EV/EBITDA of 6.43x and Price/Sales of 0.72x further reinforce a valuation profile that appears inexpensive on absolute measures, potentially discounting cyclical risks. Historical context for the valuation is unavailable as historical ratio data is not provided, making it impossible to determine if the current P/E is near the top or bottom of its own historical range; this lack of historical benchmark limits the ability to assess whether current levels represent a value opportunity or reflect justified pessimism.
PE
7.5x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
6.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: TMHC's primary financial risk is its inherent cyclicality, as its revenue and earnings are directly tied to the health of the U.S. housing market. While the balance sheet is strong (D/E of 0.37), the company's profitability (net margin of 9.63%) is susceptible to margin compression from rising input costs, labor shortages, or a decline in home prices. The lack of a clear, high-growth revenue trajectory, as suggested by flat analyst estimates around $7.25B, means the stock relies on operational execution and market conditions rather than secular growth to drive returns.
Market & Competitive Risks: The stock faces significant valuation compression risk if the market continues to de-rate cyclical equities, especially given its high beta of 1.58 which amplifies market moves. Competitive risks are inherent in a fragmented industry, and the company's geographic concentration in high-growth markets (with the West segment as the majority revenue contributor) exposes it to regional economic downturns. The stock's massive underperformance (-27.5% relative strength over 1 year) indicates it is already out of favor, creating a risk of further sector rotation away from housing-related names if macroeconomic conditions deteriorate.
Worst-Case Scenario: The worst-case scenario involves a sharp downturn in the U.S. housing market triggered by persistently high interest rates, leading to a significant drop in new home orders, cancellations, and price cuts. This would compress TMHC's margins and likely result in earnings missing the current forward EPS estimate of $6.64. In this adverse scenario, the stock could realistically retest its 52-week low of $54.58, representing a downside of approximately -10% from the current price of $60.64. A breach of that support could trigger a new leg down, potentially approaching the -22.2% maximum drawdown level observed in its recent trading history.
FAQ
The key risks are: 1) Macroeconomic & Interest Rate Risk: As a homebuilder, TMHC is hyper-sensitive to mortgage rates and economic cycles (Beta 1.58). 2) Cyclical Downturn Risk: A housing slowdown could rapidly erode its 9.63% net margin and $7.25B revenue base. 3) Sentiment & Volatility Risk: The stock has shown a 22.2% max drawdown and severe underperformance, indicating it is prone to sharp declines when out of favor. 4) Execution Risk: While the balance sheet is strong, operational missteps in a tough market could worsen results. The macroeconomic risk is currently the most severe.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $58 and $65, reflecting a continuation of current range-bound action amid a stagnant housing market. The Bull Case (25% probability) targets $70 to $75 on a housing recovery and multiple expansion. The Bear Case (15% probability) warns of a drop to $50-$55 if the housing market deteriorates. The base case is most likely, anchored by the company's ability to meet its estimated EPS of $6.64 but lacking a catalyst for a major re-rating.
On absolute measures, TMHC appears significantly undervalued, trading at a trailing P/E of 7.45x, a Price/Sales of 0.72x, and an EV/EBITDA of 6.43x. These multiples are typically associated with value stocks and suggest the market is pricing in substantial cyclical risk. Without a sector average for direct comparison, the valuation implies the market expects stagnant growth or a potential earnings decline. Therefore, the stock is likely undervalued if the housing market stabilizes, but fairly valued or overvalued if a severe downturn materializes.
TMHC is a speculative buy only for investors with a high risk tolerance and a contrarian value mindset. The stock trades at a very low P/E of 7.45x and has a fortress balance sheet (D/E 0.37), which provides a margin of safety. However, it is a poor buy for most investors due to its severe underperformance (-27.5% vs. market over the past year), high volatility (beta 1.58), and dependence on a favorable turn in the interest rate cycle. It could be a good buy for a patient investor betting on a housing recovery, but timing that entry is exceptionally difficult.
TMHC is unsuitable for short-term trading due to its high volatility (beta 1.58) and lack of clear near-term catalysts, which make timing entries and exits difficult. It is better suited for a long-term, cyclical investment horizon of 3-5 years, allowing an investor to potentially ride out the housing cycle and benefit from a eventual recovery. The stock does not pay a dividend, eliminating it as an income holding. Therefore, only investors with a long-term view who can stomach significant interim volatility should consider a position.
